Late-stage biopharmaceutical company Soligenix Inc. today announced it has entered into a definitive license agreement with the University of Colorado (CU) for novel technology to develop subunit vaccines with long-term stability, including stability at elevated temperatures.

Soligenix’s technology is the subject of several United States and foreign patent applications involving the use of adjuvants in combination with vaccines designed to resist thermal inactivation. The company has been developing this technology under an agreement from CU supported by a $9.4 million grant from the National Institute of Allergy and Infectious Diseases (NIAID).

The company said the license agreement expands scope for thermostable vaccines for biodefense in addition to potential vaccine indications. Soligenix’s stabilization technology is being used to advance RiVax™, its subunit vaccine against ricin toxin, as well as a subnit vaccine for anthrax prevention.

“The achievement of extended stability as well as stability under elevated temperature would represent a significant step forward in vaccine technology. These properties are not shared with conventional vaccines that require refrigeration,” Robert N. Brey, PhD, chief scientific officer of Soligenix stated in the press release. “Lack of long-term stability is a significant problem in vaccines for use in emergency situations and especially for vaccines used in the developing world where the cold storage chain is difficult to maintain. Further, this novel thermostability technology has the potential to allow us to expand our vaccine business into the development of countermeasures against other more common infectious diseases.”

Theodore Randolph, PhD, professor of Chemical and Biological Engineering at CU-Boulder, noted the importance of vaccines in the overall healthcare market, and detailed issues that the stabilization technology has the potential to address.

“Vaccines are a valuable part of our healthcare arsenal, providing great benefit per dollar spent,” Dr. Randolph stated. “Most current vaccines, however, require carefully controlled cold storage conditions to retain their potency and safety. This adds cost and greatly complicates strategies for their use, especially in public health emergencies or in developing countries. We are pleased that Soligenix has licensed our technology, which offers the potential to create vaccine formulations whose enhanced thermostability allows them to be stockpiled and delivered to patients with much less stringent temperature control requirements.”

For more information visit www.soligenix.com